diflunisal has been researched along with Back Pain in 13 studies
Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.
diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.
Back Pain: Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An open trial with diflunisal (500 mg twice daily) in 766 outpatients consulting their doctor for low back pain, was carried out as part of the project "Back Pain 1981" in Finland." | 9.06 | Diflunisal in the treatment of low back pain in a multicentre study. ( Himanen, P; Hurme, M, 1986) |
| "Thirty-seven patients with chronic back pain were entered into a randomised, 3-way, double-blind, cross-over comparison of naproxen sodium 550 mg twice daily, diflunisal 500 mg twice daily, and placebo." | 9.05 | Naproxen sodium, diflunisal, and placebo in the treatment of chronic back pain. ( Berry, H; Bloom, B; Hamilton, EB; Swinson, DR, 1982) |
| " The dosage of diflunisal was 500 mg twice daily (d-group) and the dosage of indomethacin 50 mg three times daily (i-group)." | 6.66 | Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago. ( Orava, S, 1986) |
| "Diflunisal was found to be an effective analgesic in mild to moderate pain of acute soft tissue injuries, and caused fewer and more tolerable side effects than did acetaminophen with codeine." | 6.66 | Treatment of mild to moderate pain of acute soft tissue injury: diflunisal vs acetaminophen with codeine. ( DeForge, B; King, DE; Muncie, HL, 1986) |
| "An open trial with diflunisal (500 mg twice daily) in 766 outpatients consulting their doctor for low back pain, was carried out as part of the project "Back Pain 1981" in Finland." | 5.06 | Diflunisal in the treatment of low back pain in a multicentre study. ( Himanen, P; Hurme, M, 1986) |
| "Seventy out-patients with acute back pain participated in a double-blind comparative trial of the clinical efficacy and tolerance of orally administered meptazinol and diflunisal." | 5.05 | Double-blind parallel study of meptazinol versus diflunisal in the treatment of lumbago. ( Heikkilä, J; Partanen, T; Videman, T, 1984) |
| "Thirty-seven patients with chronic back pain were entered into a randomised, 3-way, double-blind, cross-over comparison of naproxen sodium 550 mg twice daily, diflunisal 500 mg twice daily, and placebo." | 5.05 | Naproxen sodium, diflunisal, and placebo in the treatment of chronic back pain. ( Berry, H; Bloom, B; Hamilton, EB; Swinson, DR, 1982) |
| " The dosage of diflunisal was 500 mg twice daily (d-group) and the dosage of indomethacin 50 mg three times daily (i-group)." | 2.66 | Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago. ( Orava, S, 1986) |
| "Diflunisal was found to be an effective analgesic in mild to moderate pain of acute soft tissue injuries, and caused fewer and more tolerable side effects than did acetaminophen with codeine." | 2.66 | Treatment of mild to moderate pain of acute soft tissue injury: diflunisal vs acetaminophen with codeine. ( DeForge, B; King, DE; Muncie, HL, 1986) |
| " In addition, diflunisal has a longer duration of action and thus requires less frequent dosing than naproxen." | 2.66 | Comparison of diflunisal and naproxen in the management of acute low back strain. ( Aghababian, RV; Heifetz, IN; Volturo, GA, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hickey, RF | 1 |
| Jägemann, V | 1 |
| Videman, T | 1 |
| Heikkilä, J | 1 |
| Partanen, T | 1 |
| Standnes, B | 1 |
| Weber, H | 1 |
| Berry, H | 1 |
| Bloom, B | 1 |
| Hamilton, EB | 1 |
| Swinson, DR | 1 |
| Basmajian, JV | 1 |
| Orava, S | 1 |
| Hurme, M | 1 |
| Himanen, P | 1 |
| Muncie, HL | 1 |
| King, DE | 1 |
| DeForge, B | 1 |
| Aghababian, RV | 1 |
| Volturo, GA | 1 |
| Heifetz, IN | 1 |
| Brown, FL | 1 |
| Bodison, S | 1 |
| Dixon, J | 1 |
| Davis, W | 1 |
| Nowoslawski, J | 1 |
| Snapinn, SM | 1 |
| Waterworth, RF | 1 |
| Hunter, IA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain[NCT00365976] | Phase 4 | 58 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe. (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 6.45 | 6.38 | 4.54 | 4.14 | 2.62 |
| Placebo | 7.10 | 6.57 | 5.53 | 5.07 | 6.21 |
The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia). (NCT00365976)
Timeframe: Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Prenaprosyn Baseline | Postnaprosyn baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 18.85 | 18.00 | 11.28 | 10.61 | 8.38 |
| Placebo | 20.26 | 16.78 | 12.85 | 12.74 | 13.75 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 38.28 | 22.36 | 17.50 | 15.28 |
| Placebo | 34.11 | 27.00 | 23.10 | 19.91 |
Nightly total sleep time was averaged from diary entries. (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, week 2, week 4
| Intervention | Minutes (Mean) | |||
|---|---|---|---|---|
| postnaprosyn baseline | week 1 | week 2 | Week 4 | |
| Eszopiclone | 316.96 | 403.47 | 421.97 | 411.97 |
| Placebo | 380.45 | 375.56 | 382.11 | 388.96 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | awakenings (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 2.29 | 1.31 | 1.35 | 1.33 |
| Placebo | 2.08 | 1.98 | 2.13 | 2.34 |
Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain) (NCT00365976)
Timeframe: postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.02 | 3.54 | 3.30 | 3.08 |
| Placebo | 3.90 | 3.82 | 4.01 | 3.80 |
"The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 yes-no items assessing potential disabilities.~Scores range from 0 (no disability) to 24 (severe disability)." (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 12.27 | 9.97 | 9.10 | 7.63 | 6.59 |
| Placebo | 11.33 | 10.30 | 9.05 | 9.32 | 7.94 |
Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep (NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.52 | 5.99 | 6.18 | 6.38 |
| Placebo | 4.44 | 4.90 | 5.33 | 5.29 |
Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, Week 2, Week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 48.51 | 40.72 | 34.70 | 31.69 |
| Placebo | 53.79 | 51.99 | 51.25 | 51.60 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 91.51 | 49.34 | 37.07 | 36.74 |
| Placebo | 81.43 | 76.71 | 81.32 | 76.18 |
13 trials available for diflunisal and Back Pain
| Article | Year |
|---|---|
Chronic low back pain: a comparison of diflunisal with paracetamol.
Topics: Acetaminophen; Adult; Aged; Back Pain; Clinical Trials as Topic; Diflunisal; Double-Blind Method; Hu | 1982 |
[Treatment of acute lumbago with diflunisal. Controlled double-blind study with placebos].
Topics: Acute Disease; Adolescent; Adult; Back Pain; Chemical Phenomena; Chemistry; Clinical Trials as Topic | 1983 |
Double-blind parallel study of meptazinol versus diflunisal in the treatment of lumbago.
Topics: Adult; Azepines; Back Pain; Clinical Trials as Topic; Diflunisal; Double-Blind Method; Female; Human | 1984 |
Evaluation of the analgetic effect of diflunisal in patients with severe radicular pain.
Topics: Acetaminophen; Back Pain; Clinical Trials as Topic; Diflunisal; Double-Blind Method; Female; Humans; | 1981 |
Naproxen sodium, diflunisal, and placebo in the treatment of chronic back pain.
Topics: Adult; Aged; Back Pain; Clinical Trials as Topic; Diflunisal; Double-Blind Method; Female; Humans; M | 1982 |
Acute back pain and spasm. A controlled multicenter trial of combined analgesic and antispasm agents.
Topics: Acute Disease; Amitriptyline; Back Pain; Diflunisal; Double-Blind Method; Drug Therapy, Combination; | 1989 |
Medical treatment of acute low back pain. Diflunisal compared with indomethacin in acute lumbago.
Topics: Adolescent; Adult; Aged; Back Pain; Clinical Trials as Topic; Diflunisal; Double-Blind Method; Femal | 1986 |
Diflunisal in the treatment of low back pain in a multicentre study.
Topics: Adolescent; Adult; Aged; Back Pain; Chronic Disease; Clinical Trials as Topic; Diflunisal; Female; H | 1986 |
Treatment of mild to moderate pain of acute soft tissue injury: diflunisal vs acetaminophen with codeine.
Topics: Acetaminophen; Acute Disease; Adult; Back Pain; Clinical Trials as Topic; Codeine; Diflunisal; Drug | 1986 |
Comparison of diflunisal and naproxen in the management of acute low back strain.
Topics: Acute Disease; Adult; Back Pain; Clinical Trials as Topic; Diflunisal; Drug Tolerance; Female; Human | 1986 |
Comparison of diflunisal and acetaminophen with codeine in the treatment of initial or recurrent acute low back strain.
Topics: Acetaminophen; Adult; Back Pain; Clinical Trials as Topic; Codeine; Diflunisal; Drug Combinations; D | 1986 |
Evaluating the efficacy of a combination therapy.
Topics: Amitriptyline; Analgesics; Back Pain; Biometry; Clinical Trials as Topic; Diflunisal; Double-Blind M | 1987 |
An open study of diflunisal, conservative and manipulative therapy in the management of acute mechanical low back pain.
Topics: Acute Disease; Adolescent; Adult; Back Pain; Clinical Trials as Topic; Diflunisal; Female; Humans; M | 1985 |